Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05905419 · ClinicalTrials.gov registry record · NA

Neuroimaging of Opioid Phase (OPAL)

A NA study of Chronic Pain and Opioid Use, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
140
Enrollment target
1
Study location

NCT05905419 is a NA study of Chronic Pain and Opioid Use that is actively recruiting participants, run by Duke University. The registered enrollment target is 140 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05905419, a NA study of Chronic Pain and Opioid Use, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
140 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare activity in the brains of female adults with chronic pain and/or opioid use, and healthy female adults that may help to develop new and targeted treatments for adults with chronic pain and alternatives to opioid therapy.

Conditions Studied

Interventions

  • OTHER Opioid Phase

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2023-06-01
Est. Completion 2027-06-30
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT05905419

The ClinicalTrials.gov registry entry for NCT05905419 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (82% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which Opioid Phase is the first listed.

NCT05905419 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05905419 about?

NCT05905419 is a clinical study titled "Neuroimaging of Opioid Phase (OPAL)". The purpose of this study is to compare activity in the brains of female adults with chronic pain and/or opioid use, and healthy female adults that may help to develop new and targeted treatments for adults with chronic pain and alternatives to opioid therapy.

What is the current status of trial NCT05905419?

This trial is currently recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2023-06-01. Estimated completion is 2027-06-30.

What conditions does trial NCT05905419 study?

This clinical trial studies the following conditions: Chronic Pain, Opioid Use.

What interventions are being tested in trial NCT05905419?

The interventions under investigation include: Opioid Phase (OTHER).

Who is sponsoring clinical trial NCT05905419?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05905419 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.